PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
October 8, 2025Frontiers in Immunology3 citationsOpen Access

Prognostic value of neutrophil to lymphocyte ratio in patients with esophagus cancer receiving neoadjuvant therapy: a systematic review and meta-analysis

View Full Paper
LMLingling MaJHJian‐Jun HePLPing Li

Key Points

  • Higher neutrophil-to-lymphocyte ratio significantly correlates with worse overall survival outcomes in esophageal cancer patients.
  • Results indicate an increase in overall survival hazard ratio of 1.99 and recurrence-free survival hazard ratio of 2.69.
  • Subgroup analyses reveal elevated NLR consistently linked with shorter recurrence-free survival across different treatment modalities.
  • Findings underscore NLR as a valuable biomarker for risk stratification in esophageal cancer management strategies.

Abstract

Background Growing research reveals a relation of the neutrophil-to-lymphocyte ratio (NLR) to clinical outcomes of the esophageal cancer (EC) population undergoing neoadjuvant therapy. However, current findings remain inconclusive and somewhat controversial. Methods PubMed, Embase, Web of Science, and the Cochrane Library were thoroughly retrieved until April 22, 2025 to collect studies on the link of NLR to prognosis among the EC population following neoadjuvant therapy. Eligible studies were selected as per predefined eligibility criteria. The primary outcomes encompassed overall survival (OS), recurrence-free survival (RFS), and pathological complete response (pCR). Hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) were pooled for prognostic significance assessment along with subgroup analyses. The evidence was graded via the GRADE method. Results 11 cohort studies involving 2,220 patients were included in the analysis. The results demonstrated a notable link of risen NLR to less favorable OS (HR = 1.99, 95% CI: 1.43–2.76, P 0.0001; I² = 88%), shorter RFS (HR = 2.69, 95% CI: 1.77–4.08, P 0.00001; I² = 47%), and lower pCR rates (OR = 0.67, 95% CI: 0.47–0.94, P = 0.02; I² = 62%). Subgroup analyses by sample size, follow-up length, age, treatment modality, and NLR cut-off value consistently demonstrated a strong correlation between elevated NLR and shortened RFS across all subgroups. Notably, in patients receiving neoadjuvant chemoradiotherapy (NCRT), the link of increased NLR to OS and RFS appeared more robust compared to those receiving neoadjuvant chemotherapy (NCT) alone. Conclusion In patients with EC undergoing neoadjuvant therapy, a higher pre-treatment NLR is significantly linked to worse OS and RFS, as well as a lower likelihood of achieving pCR. Therefore, NLR can be a valuable prognostic biomarker in this patient population, potentially aiding clinicians in risk stratification and treatment decision-making. Systematic review registration https://www.crd.york.ac.uk/prospero/ , identifier CRD42024610088.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Ma et al. (2025) studied this question.

synapsesocial.com/papers/68e5c1ba6950a706b22b553fhttps://doi.org/10.3389/fimmu.2025.1615962
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The PRISMA 2020 statement: an updated guideline for reporting systematic reviews2021 · 104,483 citations
  2. 2Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries2024 · 25,401 citations
  3. 3Peripheral blood cell count ratios are predictive biomarkers of clinical response and prognosis for non‐surgical esophageal squamous cell carcinoma patients treated with radiotherapy2020 · 17 citations
  4. 4Global Burden of 5 Major Types of Gastrointestinal Cancer2020 · 2,042 citations
  5. 5Elements of cancer immunity and the cancer–immune set point2017 · 5,478 citations